Work

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Year: 2023

Type: article

Abstract: [Figure: see text]

Source: Blood Advances

DOI: 10.1182/bloodadvances.2023010223

Authors: Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Ariela Noy, Wyndham H. Wilson, Mark Roschewski

Institutions: National Cancer Institute, Center for Cancer Research, Georgetown University, Massachusetts General Hospital, University of Iowa, Wake Forest University Health Sciences, Wake Forest University, National Institutes of Health, University of Rochester Medicine, University of Rochester, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

Funders: National Institutes of Health, National Cancer Institute

Awards: G1938688226, G1974211183, G2687197464, G554930679, G630064964, G9000097678, G9000351610, Cancer Center Support Grant, Cancer Center Support Grant, Consortium for Advancing Management and Prevention of Cancer in People with HIV

OpenAlex ID: W4382631400

FWCI:

Cites: 17

Cited by:

Related to: 10